We have isolated a human cDNA clone encoding a novel protein of 22 kDa that is a human counterpart of the rat oncoprotein PTTG. We show that the corresponding gene (hpttg) is overexpressed in Jurkat cells (a human T lymphoma cell line) and in samples from patients with dierent kinds of hematopoietic malignancies. Analysis of the sequence showed that hPTTG has an aminoterminal basic domain and a carboxyl-terminal acidic domain, and that it is a proline-rich protein with several putative SH3-binding sites. Subcellular fractionation studies show that, although hPTTG is mainly a cytosolic protein, it is partially localized in the nucleus. In addition we demonstrate that the acidic carboxyl-terminal region of hPTTG acts as a transactivation domain when fused to a heterologous DNA binding domain, both in yeast and in mammalian cells.
Introduction
Cancer is a disease of genes that arises via a multistep process in which a normal somatic cell progresses to a fully malignant tumor through a recurrent mechanism of clonal expansion triggered by genetic lesions (Vogelstein and Kinzler, 1993) . These lesions include mutations, but also aberrant expression, of protooncogenes or tumor suppressor genes.
Gene transcription is a key regulatory point in diverse developmental processes such as cell growth, dierentiation, apoptosis and transformation. The transcription factors are often tightly regulated and the activities of these proteins can be modi®ed at a variety of levels. Their inappropriate expression may subvert normal programs of cell proliferation, differentiation, and survival. Genes coding for transcription factors are the most frequently aected by altered expression in acute leukemias, emphasizing the critical role of these regulatory molecules in blood cells development (Shivdasani and Orkin, 1996) . Activation of transcription factors such as myc, hox11, lmo1, lmo2, tall, lyl1, tal2, aml1, cbfb, mll and pbx is involved in acute leukemias (reviewed in Hwang and Baer, 1995; Look, 1997) . However, a much larger number of genes are probably involved in primary and secondary processes responsible for the acquisition of the phenotype of tumor cells. Identi®cation of these genes and analysis of their functions is helping eorts to understand the mechanisms of tumorigenesis, as well as the normal physiology of eukaryotic cells.
The rat protein PTTG (Pei and Melmed, 1997) was identi®ed because of the dierential expression of its mRNA in pituitary tumor cells. Its overexpression was able to induce cell transformation in vitro in mouse 3T3 cells, and tumor formation in nude mice.
Now we have cloned a human cDNA homologue of pttg. This gene, named hpttg, is overexpressed in Jurkat cells as well as in leukocytes from patients with dierent kinds of hematopoietic neoplasms or myelodysplastic syndromes. In contrast, its expression in samples obtained from normal donors is very low or undetectable. Analysis of the sequence showed that the protein contains an amino-terminal basic domain and a carboxyl-terminal acidic domain. In many eukaryotic transcription activators, the presence of an acidic region in the carboxyl terminus correlates with the transactivation domain (Ptashne, 1988) . Importantly, we demonstrate that the acidic C-terminal region of hPTTG acts as a transactivation domain when fused to a heterologous DNA binding domain.
Results

Molecular cloning of human pttg cDNA
After screening a Jurkat cell oligo(dT) cDNA library by the yeast two-hybrid system with Grb3-3 (an isoform of Grb2) as a bait, several positive clones were isolated (Ramos-Morales et al., 1997). The cDNA insert from one of these clones (g24) contained a 700 base pairs (bp) insert and carried a poly-A tail as expected. An open reading frame was detected in these sequence but the ®rst ATG codon was not preceded of any in-frame stop codon. In order to obtain additional sequence, a screening of a lgt11 human thymus oligo(dT) cDNA library was performed using the insert from clone g24 as a probe. Three clones were obtained and the cDNA inserts were subcloned into pBluescript and sequenced. The three clones were dierent in size but identical in the overlapping sequence.
As shown in Figure 1a , the longest sequence comprises 787 bp and contains an open reading frame of 609 bp. The presence of an in-frame stop codon upstream of the predicted initiation codon indicates that the complete coding sequence was present in this clone as well as in g24. The predicted protein sequence consists of 202 amino acids and has a calculated molecular mass of 22 024 daltons and a pI of 6.55.
The PROSITE Dictionary of Protein Sites and Patterns revealed consensus motifs for cyclic AMP and cyclic GMP dependent protein kinase phosphorylation, casein kinase II phosphorylation and protein kinase C phosphorylation. The secondary structure and charge display of the protein was predicted using the programs PeptideStructure and Pepstats (not shown). According to these analyses, the protein can be divided in an amino-terminal basic domain (amino acids 1 to 101) of pI 11.2 and a carboxyl-terminal acidic domain (amino acids 102 to 202) of pI 3.8. It is of note the high content in prolines (12%) and the presence of several proline motifs that could mediate interaction with SH3 domain containing proteins (Figure 1b) .
When the cDNA sequence was used to search the EMBL and GenBank data bases for homologous sequences, 79% identity was found with a recently isolated rat gene, pttg, that is exclusively expressed in pituitary tumor cell lines but not in normal pituitary (Pei and Melmed, 1997) . The predicted human PTTG protein was 72% identical and 82% similar to the rat protein ( Figure 1c) . A search on the EST division of GenBank revealed many partial human sequences identical to g24. There were not human EST sequences more similar to rat pttg than the sequence contained in g24, so it probably corresponds to the human counterpart of pttg. To con®rm this, g24 insert was used to screen a lZAPII rat testis oligo(dT) cDNA library. All clones obtained were identical to rat pttg in the coding region. Table 1 summarizes the results obtained when the predicted amino acid sequence of the new protein was used in a similarity search performed on databases SWISSPROT+TREMBL+TREMBLNEW with the Washington University version of the program BLASTP. The accession number, species, name, per cent of identity and similarity and length of similar segments are given for the ten sequences producing the highest scores. The highest score corresponds to rat PTTG. Most of the rest are histones or other DNAbinding proteins, including a known transcription factor: mouse stromelysin PDGF responsive element binding protein transcription factor (Sanz et al., 1995) .
In vitro transcription and translation of human pttg and analysis of expression by Western blotting To molecularly characterize the human PTTG (hPTTG) protein, a set of experiments was performed. First, as shown in Figure 2a , translation of the in vitro transcribed g24 clone generated a product hpttg is overexpressed in leukemiaof apparent molecular mass of approximately 29 kDa on SDS ± PAGE. Next, hPTTGDC124, a fragment of clone g24, was subcloned into a pGEX-4T-2 bacterial expression vector in order to overproduce a glutathione-S-transferase (GST) fusion protein containing amino acids 1 to 123 from human PTTG. A polyclonal antiserum was raised in rabbit against the GST fusion protein. The resulting immune rabbit serum (antihPTTG) reacted strongly with the fusion protein and with both GST and hPTTG moieties obtained after thrombin treatment (Figure 2b ). The expression of hpttg was assessed in Jurkat cells by Western blotting with the rabbit polyclonal serum. Nonidet P-40 lysates were resolved by SDS ± PAGE, transferred to a nitrocellulose ®lter, and revealed with the polyclonal serum anti-hPTTG. A band of apparent molecular mass of 29 kDa was observed, con®rming the result obtained by in vitro transcription and translation of clone g24 (Figure 2c ).
Tissue distribution of human pttg
To investigate the expression of human pttg (hpttg), Northern blot analysis of mRNA from dierent human adult tissues was performed with g24 insert as a probe. As seen in Figure 3 , a single band of about 900 bp was observed in some tissues. High level of expression is observed in testis, thymus and placenta. Very low or undetectable expression levels were observed in spleen, prostate, ovary, peripheral blood leukocytes, heart, brain, liver, skeletal muscle, kidney and pancreas.
hpttg is overexpressed in hematopoietic tumors
The low expression of hpttg in leukocytes (some expression is observed after long exposure in the Northern blotting), together with the fact that g24 clone was obtained from Jurkat cells, prompted us to compare the expression of this mRNA in normal T lymphocytes and Jurkat T cells. Northern blot analysis showed a high expression in Jurkat cells whereas it was not detected in isolated peripheral T lymphocytes ( Figure 4 , left panel). Next the expression of hpttg was assessed in samples from patients with leukemia, lymphoma or myelodysplastic diseases ( Figure 4 , right panel). Twenty out of 28 patients (70%) expressed detectable levels of hpttg, in contrast with healthy donors, indicating that overexpression of this gene is correlated with hematopoietic diseases.
Subcellular localization of hPTTG
The localization of hPTTG was examined in Jurkat cells by subcellular fractionation. Western blot experiments performed on cytosol and nuclear fractions showed that hPTTG is mainly located in the cytosol. However, it is also partially localized in the nucleus ( Figure 5 ). Quanti®cation of the bands by scanning densitometry shows that about 15% of hPTTG is present in the nucleus of Jurkat cells. This Equal amounts of total RNA from Jurkat cells and isolated T lymphocytes from normal donors were used for Northern blot analysis. Right panel: Expression of hpttg in hematopoietic neoplasms. Total RNA from samples isolated from patients with the following hematopoietic diseases were used for Northern blot analysis: 1, plasmocytomas; 2, acute monoblastic leukemias; 3, acute myelomonocytic leukemia; 4, acute erythroleukemia; 5, acute promyelocytic leukemia; 6, chronic myelomonocytic leukemia (chronic phase); 7, refractory anemia with ringed sideroblasts; 8, refractory anemia with excess blasts; 9, thrombocytemia; 10, follicular lymphoma; 11, Hodgkin's lymphoma; 12, lymphoplasmoide lymphoma. RNA from normal perypheral blood leukocytes is included in 13. RNA concentrations were determined by optical density and equal amounts of each sample were loaded. g24 cDNA was used as a probe hpttg is overexpressed in leukemia A Â Domõ Ânguez et al estimation largely exceeds the 1% calculated of maximal contamination of cytosolic proteins in the nuclear fraction (see the Materials and methods section).
hPTTG exhibits transcriptional activity in yeast
The similarity of hPTTG to DNA-binding proteins together with the partial nuclear localization of the protein and the presence of an excess of negative charged residues in the C-terminal region, may suggest a function of hPTTG in transcription activation. In order to investigate this possibility, g24 insert was subcloned into the two-hybrid vector pGBT9 to obtain a fusion between Gal4 DNA-binding domain and hPTTG. Saccharomyces cerevisiae strain HF7c, containing his3 and lacZ reporter genes under the control of Gal4-responsive elements, was transformed with plasmid pGBT9-hPTTG alone and tested for growth on selective medium and for b-galactosidase activity. pGBT9-hPTTG was able to induce b-galactosidase activity and to promote growth of HF7c in selective medium even when this medium was supplemented with 5 mM 3-amino-1,2,4-triazole ( Figure 6 ). In order to elucidate the domain involved in this activation two subclones were made in the vector pGBT9. As seen in Figure 6 , strain HF7c transformed with pGBT9-hPTTGDN122 (lacking amino acids 1 ± 122) was still able to grow in selective medium, whereas the same strain carrying plasmid pGBT9-hPTTGDC124 (lacking amino acids 124 ± 202) was not. These results show that the carboxyl-terminal domain of hPTTG is able to display a strong transcriptional activity in yeast.
hPTTG transcriptional activity in mammalian cells
To rule out the possibility that hPTTG activates transcription only in the yeast system, we examined the transcriptional activity of this protein using a mammalian cell line, Cos-7. g24 insert was subcloned into the vector pGAL4. Cos-7 cells were cotransfected with this plasmid and with the pGAL4-4TK-luc luciferase reporter plasmid. As seen in Figure 7 , hPTTG shows transcriptional activity of the same level than the activity displayed by GAL4-VP16 (Sadowski et al., 1988) , a strong transcriptional activator used as a positive control. Subclones hPTTGDN122 and hPTTGDC124 were also prepared in the vector pGAL4. Subclone hPTTGDN122 showed the same transcriptional activity as the full length hPTTG whereas subclone hPTTGDC124 was not able to activate transcription to a detectable level (Figure 7) . Similar results were obtained in mouse NIH3T3 cells (not shown). These results con®rm and extend the data obtained in yeast. 5 Jurkat cells were separated on SDS ± PAGE, transferred to nitrocellulose membrane and then probed with anti-hPTTG polyclonal antibody. The same ®lter was reblotted with anti-Raf1 polyclonal antibody and anti-hnRNP C monoclonal antibody, respectively, to control the purity of the fractions. Exposure of 2 min using epichemiluminescence Western immunoblotting system (ECL, Amersham) Figure 6 Transcriptional activation by hPTTG in yeast. Hf7c reporter strain was transformed with pGBT9 alone (7), pGBT9-hPTTG (hPTTG), pGBT9-hPTTGDC124 (hPTTGDC) or pGBT9-hPTTGDN122 (hPTTGDN). Growth in the absence of histidine and with 5 mM of 3-amino-1,2,4-triazole indicates transactivation. Each patch represents an independent transformant. There are four patches for every strain 
Discussion
In this study we report the isolation and characterization of a human counterpart of the rat gene pttg (for pituitary tumor-transforming gene) (Pei and Melmed, 1997) . pttg mRNA is highly expressed in GC and GH 4 rat pituitary tumor cell lines but not in normal pituitary or osteogenic sarcoma cells. Transfection experiments in mouse 3T3 cells and injection of transfected cells into athymic nude mice showed that pttg is a potent transforming gene. We have isolated hpttg cDNA from a Jurkat cDNA library. This fact together with the low expression observed in normal peripheral blood leukocytes prompted us to investigate the expression of this gene in normal T lymphocytes, Jurkat T cells and samples from healthy donors and from patients with leukemia or other hematopoietic neoplastic disorders. Our data show that hpttg is overexpressed not only in Jurkat cells but also in a high proportion of the primary tumors examined, indicating that this is not an artifact of cell culture. These results show an aberrant expression of the hpttg gene in leukemic cells and suggest the involvement of this gene in leukemogenesis.
The mechanism that leads to ectopic expression of hPTTG is unknown. However, chromosomal translocations are present in a high proportion of leukemias. These structural rearrangements may activate protooncogenes that are silent or expressed at low levels in the progenitors cells of a particular lineage by placing them under the control of potent enhancer elements within the regulatory region of a gene that is normally highly expressed. Chromosomal translocations are found in 65% of acute leukemias (Look, 1997); a chromosome translocation to the IgH locus, most frequently into a switch region, is a nearly universal event in myeloma cell lines, and it appears to be equally frequent in primary tumor samples (Hallek et al., 1998) . Studies of chromosome abnormalities associated with T cell acute leukemias have implicated an increasing number of dierent protooncogenes (Hwang and Baer, 1995) . Chromosomal mapping of the hpttg gene in normal and leukemic cells could help to understand the cause of its aberrant expression.
Among adult tissues examined, testis is the only tissue that expresses rat pttg. We have studied 16 human adult tissues and we show that hpttg is expressed at high level in testis but also in thymus and placenta. Interestingly these organs are immune privileged sites. Immune privilege is a mechanism to protect some organs against dangerous and unwanted immune reactions (see Streilein (1993) for a review). Expression of FasL (the ligand for Fas/APO-1/CD95, a member of the TNF receptor superfamily) has been recently involved in immune privilege (Bellgrau et al., 1995; Grith et al., 1995) . This mechanism may also account for the ability of tumor cells to evade immune destruction. A relationship between overexpression of hPTTG and immune privilege would be an attractive mechanism to explain the tumorigenic potential of hPTTG that deserves further studies. On the other hand, comparison of the high expression observed in thymus with the undetectable levels observed in normal T cells suggests a role of hPTTG in normal hematopoietic development.
Transcriptional activators are typically composed of distinct domains including separable DNA-binding and activation domains (for a review, see Triezenberg, 1995) . This feature allows the use of a heterologous binding domain to study the activation domains when the physiological targets of a transcription factor have not been de®ned. This approach has been used to identify transcriptional domains in the oncoproteins BRCA1 (Chapman and Verma, 1996; Monteiro et al., 1996) and BRCA2 (Milner et al., 1997) . By using the same approach, we show that the C-terminal portion of hPTTG (amino acids 123 ± 202) is able to activate transcription of the his3 and lacZ genes in S. cerevisiae HF7c as well as the luciferase gene in mammalian cells, all driven by GAL4 responsive elements. Interestingly, the activation observed in mammalian cells has the same level as that displayed by VP16, used for comparison, and considered as a very strong activator (Sadowski et al., 1988) . These results provide insight into the potential function of the hPTTG protein. They suggest that this protein has the ability to stimulate transcription.
The activation domains have been classi®ed depending on whether they are rich in acidic amino acids, glutamine or proline. Several mammalian proteins containing acidic-rich and/or proline-rich activation domains have been shown to stimulate transcription in S. cerevisiae (Lech et al., 1988; Metzger et al., 1988; Sadowski et al., 1988; Schena and Yamamoto, 1988; Struhl, 1988) and in Schizosaccharomyces pombe (Remacle et al., 1997) . The domain of hPTTG that shows transactivation capacity (amino acids 123 ± 202), although rich in proline, seems to belong to the acidicrich class since it contains 19% of acidic amino acids and has a net charge of 712.
Subcellular fractionation studies indicated that hPTTG is mainly cytoplasmic and partially localized in the nucleus. The controls of the purity of subcellular fractions included in Figure 5 demonstrate that there is no signi®cant leakiness from one fraction to another and so the nuclear proportion of hPTTG is low but signi®cant. A modulation of this localization could occur under proper conditions. This behaviour is observed in known transcriptional activators. The Stat proteins, for instance, are cytoplasmic in non-stimulated cells. In response to IFN-a treatment, Stat 1a, Stat 1b and Stat 2 become tyrosine-phosphorylated and migrate to the nucleus where they join a 48 kDa DNA-binding protein and subsequently direct the transcription at IFN-a responsive elements (Darnell, 1997) .
De®nite con®rmation that transcriptional activation exhibited by hPTTG is physiologically relevant must await the demonstration of its DNA-binding activity, or its interaction with a DNA-binding protein, together with the identi®cation of its target genes.
Materials and methods
Two-hybrid screen
A cDNA library from Jurkat cell polyadenylated RNA constructed in fusion with Gal4-activation domain in pGAD1318 (Hannon et al., 1993) was used (Bartel et al., 1993) . S. cerevisiae strain Hf7c (MAT a trpl-901 leu2-3,112 his3-200 ura3-52 lys-801 ade2-101 canr gal4-542 gal80-538 LYS2::GAL1-HIS3 URA3::Gal4 binding site-CYC1-lacZ) hpttg is overexpressed in leukemia A Â Domõ Ânguez et al was grown at 308C in YPD medium containing 1% yeast extract, 2% polypeptone and 2% glucose, and it was sequencially transformed with pGBT-Grb3-3 and the Jurkat cell cDNA library by the lithium acetate method (Sherman et al., 1986) . Double transformants were plated on yeast drop-out medium lacking tryptophan and leucine (Sherman et al., 1986) . They were grown for 3 days at 308C and then colonies were patched on the same medium and replica-plated on Whatman 40 ®lters, to test the bgalactosidase activity (Breeden and Nasmyth, 1985) , and on yeast drop-out media lacking tryptophan and leucine and supplemented with 5 mM 3-amino-1,2,4-triazole (Sherman et al., 1986) (the Gal4-Grb3-3 fusion protein had a weak transcriptional activity if yeast grew only in selective medium). Positive clones were rescued and tested for speci®city by retransformation into Hf7c either with pGBT-Grb3-3 or with irrelevant targets.
cDNA cloning and sequence analysis Clone g24, obtained after screening by the two-hybrid system, was subcloned in pGBT9 for transactivation experiments in yeast, and in pGAL4 for transactivation experiments in Cos-7 cells. The entire g24 insert was used as a probe to hybridize against a human thymus cDNA lgt11 library. The clones obtained were isolated and subcloned into pBluescript plasmid. The nucleotide sequence was determined by using an automated sequencer from Pharmacia.
Nucleic acids and protein sequences were analysed by the University of Wisconsin Genetics Computer Group sequence analysis software package version 8.1 for UNIX computers (Devereux et al., 1984) . Comparisons to known sequences were performed by BLAST (Altschul et al., 1990) on the Internet server. Secondary structure analysis was conducted with the software programs Pepstats and PeptideStructure (Kyte and Doolittle, 1982; Chou and Fasman, 1978; Garnier et al., 1978) .
Patients
Peripheral blood, bone marrow or lymph nodes samples were obtained from patients who had been referred to the Hematology Department at HoÃ pital Cochin (Paris). All specimens were collected before the initiation of therapy and were obtained from patients with hematopoietic disorders. The diagnosis was established on the basis of morphologic and cytochemical staining, and the patients were classi®ed according to the criteria of the FrenchAmerican-British committee.
mRNA preparation and Northern blot analysis
A poly(A) + RNA blot from Clontech was hybridized with 32 P-labeled cDNA insert from clone g24 and washed as described in the manufacturer's instructions. The membrane was stripped and rehybridized to a human b-actin cDNA control probe. Peripheral blood or bone marrow cells were isolated after Ficoll-Hypaque density gradient centrifugation and washed three times in Hank's balanced salt solution. RNA was extracted by the guanidium thiocyanate procedure. After precipitation in ethanol at 7208C, RNA pellets were resuspended in water. RNA concentrations were determined by optical density, and samples were frozen at 7808C until use. RNA samples (10 mg of total RNA) were denatured in glyoxal, dimethyl sulfoxide and phosphate buer at 608C during 10 min, sizefractionated by electrophoresis through 1% agarose gel and transferred to nylon membrane. Membranes were hybridized with random 32 P-labeled probe and washed under stringent conditions. The probe used in this study was the cDNA insert from clone g24.
Preparation of GST fusion proteins and rabbit anti-hPTTG fusion protein antibodies
A fusion protein containing the complete insert from g24 was constructed at the carboxyl terminus of GST using the prokaryotic expression vector pGEX-4T-2. The subclone GST-hPTTGDC124 (lacking aminoacids 124 ± 202) was also generated. Plasmids were transformed in Escherichia coli strain DH5a. Expression of the GST fusion proteins was induced by the addition of 1 mM isopropyl-b-Dthiogalactoside and the fusion proteins were isolated from bacterial lysates by anity chromatography with glutathione-agarose beads (Sigma). hPTTG was released from the fusion protein by treatment with 1% (w/w) thrombin in cleavage buer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2.5 mM CaCl 2 ) for 2 h at 258C. A polyclonal antibody was generated in rabbit using the GST-hPTTGDC124 fusion protein. The antiserum obtained after the fourth immunization, named antihPTTG, was used in the experiments described.
Electrophoresis and immunoblot analyses
Proteins were separated by SDS ± PAGE on 10%, 12% or 15% acrylamide gels (Laemmli, 1970) and stained with Coomassie brilliant blue. Gels were electrophoretically transferred to nitrocellulose ®lters (Towbin et al., 1979) and immunoblot analyses were carried out as described (Rios et al., 1994) .
Cell culture, lysis and subcellular fractionation
Simian Cos-7 cells were cultured in Dulbeco's modi®ed Eagle's medium (DMEM) supplemented with 10% foetal calf serum. Jurkat cells were cultured in RPMI medium supplemented with 10% foetal calf serum. 2 mM Lglutamine, 100 U/ml penicillin and 100 mg/ml streptomycin were included in all culture media. All cells were mantained in a 5% CO 2 humidi®ed atmosphere at 378C. For cell lysis, 2610 7 to 10 8 cells per ml were incubated at 48C in NP40 buer (10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 10% glycerol, 1% NP40, 1 mM vanadate, 1% aprotinin, 1 mM PMSF, 1 mg/ml pepstatin and 1 mg/ml leupeptin) for 20 min. The extract was centrifuged at 20 000 g for 20 min and the supernatant was stored at 7808C.
Jurkat cell cytosol and nuclear fractions were prepared essentially as previously described (Dignam et al., 1983) . Monoclonal anti-hnRNP C (4F4) antibodies (provided by Dr G Dreyfuss, University of Pennsylvania) (Dreyfuss et al., 1984) and polyclonal anti-Raf1 antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, USA) were used in Western blot to control the purity of the fractions. Quanti®cation of the bands by scanning densitometry indicated that 99% of Raf1, a cytosolic marker, was found in the cytosol, whereas 98% of hnRNPC, a exclusively nuclear protein, was recovered in the nuclear preparation.
Transactivation assays in mammalian cells
Cos-7 cells were grown until con¯uent. Cells were cotransfected with plasmids pGAL4 (Moriggl et al., 1997) , pGAL4-VP16, pGAL4-hPTTG, pGAL4-hPTTGDN122 or pGAL4-hPTTGDC124 all together with reporter plasmid pGAL4-4TK-luc (Moriggl et al., 1997) . Cells were harvested 48 h after transfection. Cells were lysed and extracts were assayed for luciferase activity as described (Seth et al., 1992) .
